Medical Marijuana, Inc. subsidiary\u00a0<\/span>Kannalife\u2122 Sciences<\/a>\u00a0<\/span>holds the first two licenses awarded to develop and commercialize drug treatments under the U.S. government\u2019s only cannabinoid patent. Kannalife\u2122 Sciences is a phyto-medical company specializing in the research and development of cannabinoid based pharmaceuticals. With nearly a dozen leading researchers\u00a0on their Scientific Advisory Board and a leadership team that features decades of experience in the pharmaceutical space, including the development of orphan drugs, Kannalife\u2122 is in a unique position to capitalize on these licenses.<\/p>\n In 1999, a group of researchers, including Nobel Laureate Julius Axelrod, filed a patent application on behalf of the National Institutes of Health (NIH) declaring that cannabis has medicinal value. Patent 6,630,507, \u201cCannabinoids as antioxidants and neuroprotectants\u201d, was awarded 4 years later in 2003 to the U.S. Department of Health and Human Services.<\/p>\n The\u00a0<\/span>\u2018507 patent<\/a>\u00a0<\/span>covers the use of cannabinoids for the development of treatments for oxidative associated and neurodegenerative diseases, like\u00a0<\/span>Alzheimer\u2019s disease<\/a>,\u00a0<\/span>Parkinson\u2019s disease<\/a>, and\u00a0<\/span>HIV<\/a>\u00a0<\/span>related dementia. Although the patent specifically mentions cannabidiol (CBD) by name for its low toxicity and beneficial effects on the human endocannabinoid system, the patent covers all cannabinoids, natural and synthetic, that can be applied as antioxidants and neuroprotectants.<\/p>\n \n \n <\/strong><\/p>\n <\/strong><\/p>\n <\/strong><\/p>\n <\/strong><\/p>\n<\/div>\n<\/div>\n In 2012, nearly a decade after being filed for the NIH, the \u2018507 patent was licensed exclusively to Kannalife\u2122 Sciences to be the first to develop cannabinoid-based pharmaceuticals for the treatment of two neurological diseases.<\/p>\n<\/div>\n<\/div>\n [\/et_pb_text][et_pb_image src=”https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2021\/09\/scientists.jpg” title_text=”scientists” align=”center” _builder_version=”4.10.7″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_image][et_pb_text _builder_version=”4.10.7″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Kannalife\u2122 Sciences will use this patent to develop a treatment for\u00a0<\/span>Hepatic Encephalopathy<\/a>\u00a0<\/span>(HE), a neurological disease caused by damage to the liver from the abuse of alcohol and prescription pills. Although HE is considered a rare disease with fewer than 200,000 yearly cases, the cost to treat it in the U.S. alone is estimated up to\u00a0<\/span>$7 billion per year<\/a>.<\/p>\n <\/p>\n <\/strong><\/p>\n HE presents a strategic pharmaceutical target for Kannalife\u2122 Sciences. Because it is a rare disease that can be life threatening, any pharmaceuticals developed for its treatment can apply for orphan drug status, allowing it to bypass steps in the clinical trial and drug approval processes. Orphan drug status also allows for market exclusivity, preventing similar competitive products from being marketed for seven years in the U.S. and 10-12 years in the EU.<\/p>\n<\/div>\n<\/div>\n Kannalife\u2122\u00a0<\/span>also sees promise<\/span><\/a>\u00a0using cannabinoid treatments for\u00a0<\/span>Chronic Traumatic Encephalopathy<\/span><\/a>\u00a0(CTE), the degenerative brain disease that results from repeated trauma to the head that is often diagnosed in athletes, specifically retired NFL players.<\/span><\/p>\n Using this patent, Kannalife\u2122 Sciences developed a synthetic CBD-like molecule called\u00a0<\/span>KLS-13019<\/span><\/a>. This synthetic cannabinoid is\u00a0<\/span>50 times more potent and 400 times less toxic<\/span><\/a>\u00a0than natural CBD, making it viable as a potential pharmaceutical treatment for HE and CTE.<\/span><\/p>\n As the first licensee of the \u2018507 patent, Kannalife\u2122 Sciences and Medical Marijuana, Inc. have a unique opportunity to develop much needed treatments for neurodegenerative and inflammation-based diseases like Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease, HE, and CTE. Neurodegenerative diseases are generally large markets, with some estimates calculating that the rate of Alzheimer\u2019s in this country is set to jump up to 1<\/span>6 million by 2050<\/span>\u00a0as Baby Boomers continue to age, suggesting a new case will be diagnosed every 33 seconds. These conditions all share the unique characteristic that their is no universal treatment. CBD may prove to be the exception.<\/span><\/p>\n<\/div>\n<\/div>\n [\/et_pb_text][et_pb_text _builder_version=”4.10.7″ _module_preset=”default” header_4_font_size=”24px” global_colors_info=”{}”][\/et_pb_text][et_pb_button button_url=”https:\/\/medicalmarijuanainc.com\/we-are-a-company-of-firsts\/” button_text=”Back To Full Timeline” _builder_version=”4.10.7″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" WE ARE A COMPANY OF FIRSTS\u00aeTHE FIRST WITH A LICENSE TO COMMERCIALIZE THE U.S. NATIONAL INSTITUTES OF HEALTH PATENT \u201cCANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS.\u201d Medical Marijuana, Inc. subsidiary\u00a0Kannalife\u2122 Sciences\u00a0holds the first two licenses awarded to develop and commercialize drug treatments under the U.S. government\u2019s only cannabinoid patent. Kannalife\u2122 Sciences is a phyto-medical company specializing in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-12","page","type-page","status-publish","hentry"],"yoast_head":"\nTHE \u2018507 PATENT COVERS THE USE OF CANNABINOIDS FOR THE DEVELOPMENT OF TREATMENTS FOR OXIDATIVE ASSOCIATED AND NEURODEGENERATIVE DISEASES, LIKE ALZHEIMER\u2019S DISEASE, PARKINSON\u2019S DISEASE, AND HIV RELATED DEMENTIA<\/strong><\/h3>\n
KANNALIFE\u2122 SCIENCES DEVELOPED A SYNTHETIC CBD-LIKE MOLECULE CALLED KLS-13019. THIS SYNTHETIC CANNABINOID IS 50 TIMES MORE POTENT AND 400 TIMES LESS TOXIC THAN NATURAL CBD.<\/strong><\/h3>\n